ID   HO-323
AC   CVCL_Z045
SY   HO 323/WIL2.NS; HO323
DR   Wikidata; Q54890090
RX   PubMed=3485476;
CC   Group: Hybridoma fusion partner cell line.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; 6-TG).
CC   Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Homozygous (from parent cell line).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Spleen; UBERON=UBERON_0002106.
DI   NCIt; C97074; Hereditary spherocytosis
DI   ORDO; Orphanet_822; Hereditary spherocytosis
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2761 ! WIL2 NS
SX   Male
AG   5Y
CA   Transformed cell line
DT   Created: 10-04-15; Last updated: 29-06-23; Version: 12
//
RX   PubMed=3485476; DOI=10.1016/0309-1651(86)90090-1;
RA   Ohashi H., Hashizume S., Murakami H., Aihara K., Shinohara K.,
RA   Omura H.;
RT   "HO-323, a human B-lymphoblastoid cell line useful for making
RT   human-human hybridomas.";
RL   Cell Biol. Int. Rep. 10:77-83(1986).
//